These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36644638)

  • 1. Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis.
    Li L; Wang L; Liu Q; Wu Z; Zhang Y; Xia R
    Front Oncol; 2022; 12():954345. PubMed ID: 36644638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis.
    Nguyen TT; Thanh Nhu N; Chen CL; Lin CF
    Cancer Med; 2023 Sep; 12(18):18767-18785. PubMed ID: 37667978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.
    Zhang Y; Li S; Wang Y; Lu Y; Xu Y; Rao Q; Wang H; Xing H; Tian Z; Tang K; Lv L; Wang M; Wang J
    Exp Hematol Oncol; 2022 Mar; 11(1):15. PubMed ID: 35317863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
    Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
    Fergusson NJ; Adeel K; Kekre N; Atkins H; Hay KA
    Front Immunol; 2023; 14():1178403. PubMed ID: 37180149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
    Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
    Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
    Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
    J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
    Becerril-Rico J; Delgado-Montes YA; Ortiz-Sánchez E
    Leuk Lymphoma; 2023; 64(11):1822-1831. PubMed ID: 37548560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Liu S; Zhang X; Dai H; Cui W; Yin J; Li Z; Yang X; Yang C; Xue S; Qiu H; Miao M; Chen S; Jin Z; Fu C; Li C; Sun A; Han Y; Wang Y; Yu L; Wu D; Cui Q; Tang X
    Blood Cancer J; 2023 Apr; 13(1):60. PubMed ID: 37095120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
    Zhu H; Deng H; Mu J; Lyu C; Jiang Y; Deng Q
    Onco Targets Ther; 2021; 14():4023-4037. PubMed ID: 34239307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
    Xiang X; He Q; Ou Y; Wang W; Wu Y
    Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
    Xu H; Guan C; Xu P; Zhou D; Xu Y; Chen B; Bai H
    Front Oncol; 2024; 14():1355643. PubMed ID: 38651157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
    Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
    Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.
    Cao HY; Wan CL; Xue SL
    Ann Hematol; 2023 Jan; 102(1):155-165. PubMed ID: 36394582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
    Huang C; Zhang HC; Ho JY; Liu RX; Wang L; Kuang N; Zheng MR; Liu LH; Li JQ
    Oncol Lett; 2020 Oct; 20(4):21. PubMed ID: 32774494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific CAR T-cells for B-cell Malignancies.
    Furqan F; Shah NN
    Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.